Oncorus, Inc.

Oncorus, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering viral immunotherapies designed to combat cancer in patients. At the forefront of its pipeline is ONCR-177, an innovative viral immunotherapy that leverages a modified herpes simplex virus type 1 (oHSV-1) platform. This candidate, administered directly into tumors, is presently undergoing Phase I clinical evaluation for a range of different cancers. Beyond this, Oncorus is advancing ONCR-GBM, an oHSV program in preclinical development targeting brain cancer via intratumoral injection. Further research includes synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. In a significant collaboration, Oncorus has partnered with MSD International GmbH (Merck) through a clinical trial and supply agreement. This partnership aims to assess the safety and tolerability of ONCR-177 when administered in combination with Merck's well-known cancer immunotherapy, KEYTRUDA, during a Phase I clinical trial involving patients with solid tumors. Established in 2015, Oncorus, Inc. maintains its headquarters in Cambridge, Massachusetts.